oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2018-17-5-27-36oncotomsk-855Research ArticleКЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯCLINICAL STUDIESЗНАЧЕНИЕ ФАКТОРОВ ПРОГНОЗА ПРИ ПРОВЕДЕНИИ ТЕРМОХИМИОЛУЧЕВОЙ ТЕРАПИИ ГЛИОБЛАСТОМ ГОЛОВНОГО МОЗГАTHE VALUE OF PROGNOSTIC FACTORS FOR GLIOBLASTOMA TREATED WITH CONCURRENT THERMOCHEMORADIOTHERAPYhttps://orcid.org/0000-0002-7171-8728РябоваА. И.RyabovaA. I.

Рябова Анастасия Игоревна, младший научный сотрудник отделения опухолей головы и шеи, Научно-исследовательский институт онкологии

634009, г. Томск, пер. Кооперативный, 5

SPIN-код: 3128-2940.  Researcher ID (WOS): D-1138-2012. Author ID: 57190937361

Anastasiya I. Ryabova, MD, Junior Researcher Assistant, Head and Neck Cancer Department, Cancer Research Institute

5, Kooperativny Street, 634009-Tomsk

Researcher ID (WOS): D-1138-2012. Author ID: 57190937361

ranigor@mail.ruНовиковВ. А.NovikovV. A.

Новиков Валерий Александрович, доктор медицинских наук, ведущий научный сотрудник отделения опухолей головы и шеи, Научно-исследовательский институт онкологии

634009, г. Томск, пер. Кооперативный, 5

Researcher ID (WOS): D-9057-2012. Author ID (Scopus): 7402005343

Valery A. Novikov, MD, DSc, Leading Researcher, Head and Neck Cancer Department, Cancer Research Institute

5, Kooperativny Street, 634009-Tomsk

Researcher ID: D-9057-2012. Author ID (Scopus): 7402005343

https://orcid.org/0000-0003-1696-427XГрибоваО. В.GribovaO. V.

Грибова Ольга Вячеславовна, кандидат медицинских наук, научный сотрудник отделения радиологии, Научно-исследовательский институт онкологии

634009, г. Томск, пер. Кооперативный, 5

 SPIN-код: 1405-1669. Researcher ID (WOS): D-7796-2012. Author ID: 55917908000

Olga V. Gribova, MD, PhD, Researcher, Radiology Department, Cancer Research Institute

5, Kooperativny Street, 634009-Tomsk

Researcher ID (WOS): D-7796-2012. Author ID: 55917908000

gribova79@mail.ruhttps://orcid.org/0000-0002-4345-7719СтарцеваЖ. А.StartsevaZh. A.

Старцева Жанна Александровна, доктор медицинских наук, заведующая отделением радиологии, Научно-исследовательский институт онкологии

634009, г. Томск, пер. Кооперативный, 5

 SPIN-код: 8121-0310. Researcher ID (WOS): E-1286-2012. Author ID (Scopus): 6506368484

Zhanna A. Startseva, MD, DSc, Head of the Radiology Department, Cancer Research Institute

5, Kooperativny Street, 634009-Tomsk

Researcher ID: E-1286-2012. Author ID (Scopus): 6506368484

zhanna.alex@rambler.ruhttps://orcid.org/0000-0003-3187-3659ГригорьевЕ. Г.GrigorievE. G.

Григорьев Евгений Геннадьевич, кандидат медицинских наук, старший научный сотрудник отделения лучевой диагностики, Научно-исследовательский институт онкологии

634009, г. Томск, пер. Кооперативный, 5

SPIN-код: 2079-2370. Researcher ID (WOS): C-8959-2012

Evgeny G. Grigoriev, MD, PhD, Senior Researcher, Diagnostic Imaging Department, Cancer Research Institute

5, Kooperativny Street, 634009-Tomsk

Researcher ID (WOS): C-8959-2012

adresprostoy@gmail.comГлущенкоС. А.GlushchenkoS. A.

Глущенко Светлана Алексеевна, кандидат медицинских наук, врач-патологоанатом отделения патоморфологии опухолей, Научно-исследовательский институт онкологии

634009, г. Томск, пер. Кооперативный, 5

SPIN-код: 2380-3406. Researcher ID (WOS): D-2336-2012

Svetlana A. Glushchenko, MD, PhD, Pathologist, Department of Pathomorphology, Cancer Research Institute

5, Kooperativny Street, 634009-Tomsk

Researcher ID (WOS): D-2336-2012

GlushchnkoSA0204@mail.ruhttps://orcid.org/0000-0003-2060-4840ПономареваА. А.PonomaryovaA. A.

Пономарева Анастасия Алексеевна, кандидат биологических наук, младший научный сотрудник лаборатории молекулярной онкологии и иммунологии, Научно-исследовательский институт онкологии

634009, г. Томск, пер. Кооперативный, 5

SPIN-код: 3185-5606. Author ID: 37116096000. Researcher ID (WOS): D-8734-2012

Anastasiya A. Ponomaryova, PhD, Junior Researcher, Laboratory of Molecular Oncology and Immunology, Cancer Research Institute

5, Kooperativny Street, 634009-Tomsk

Author ID: 37116096000. Researcher ID (WOS): D-8734-2012

anastasia-ponomaryova@rambler.ruhttps://orcid.org/0000-0002-9866-4854СыркашевВ. А.SirkashevV. A.

Сыркашев Владимир Анатольевич, кандидат медицинских наук, ассистент кафедры неврологии и нейрохирургии

634050, г. Томск, Московский тракт, 2

SPIN-код: 8297-9139. Researcher ID (WOS): S-6110-2016

Vladimir A. Sirkashev, MD, PhD, Assistant of the Department of Neurology and Neurosurgery

2, Moskovskiy Tract, 634050-Tomsk

Researcher ID (WOS): S-6110-2016

v.syrkashev@mail.ruТомский национальный исследовательский медицинский центр Российской академии наукРоссияTomsk National Research Medical Center, Russian Academy of SciencesRussian FederationФГБУ ВО «Сибирский государственный медицинский университет» Минздрава РоссииРоссияSiberian State Medical UniversityRussian Federation2018011120181752736Copyright © Рябова А.И., Новиков В.А., Грибова О.В., Старцева Ж.А., Григорьев Е.Г., Глущенко С.А., Пономарева А.А., Сыркашев В.А., 20182018Рябова А.И., Новиков В.А., Грибова О.В., Старцева Ж.А., Григорьев Е.Г., Глущенко С.А., Пономарева А.А., Сыркашев В.А.Ryabova A.I., Novikov V.A., Gribova O.V., Startseva Z.A., Grigoriev E.G., Glushchenko S.A., Ponomaryova A.A., Sirkashev V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/855

Лечение глиобластом головного мозга является актуальной проблемой, поскольку сопровождается высокой инвалидизацией и низкой выживаемостью. Стандартная комбинированная терапия не позволяет излечить пациента, и в настоящее время ведется постоянный поиск новых методов лечения.

Материал и методы

Материал и методы. В условиях НИИ онкологии ТНИМЦ РАН выполнено исследование, включившее 30 пациентов с впервые выявленной глиобластомой головного мозга, которым проводилось комбинированное лечение по схеме: адъювантный курс химиолучевой терапии с темозоломидом с радиосенсибилизацией локальной гипертермией.

The treatment of patients with glioblastoma continues to be one of the greatest challenges. Glioblastoma is the most aggressive malignant primary brain tumor and is the most lethal among all cancers. Despite advances in the standard treatment, the prognosis for patients with glioblastoma remains poor, therefore, the development of novel treatment strategies is required.

Material and methods

Material and methods. Our study included 30 patients with newly diagnosed glioblastoma, who underwent concurrent chemoradiotherapy and local hyperthermia.

Results

Results. The median disease-free and overall survival rates were 9.6 months and 23 months, respectively. The analysis of clinical, molecular-genetic and prognostic factors related to treatment modality showed statistically significant differences in survival between patient groups representing different times for starting adjuvant therapy after surgery. The median disease-free survival was significantly higher in patients who received chemoradiotherapy with local hyperthermia within 6 weeks after surgery than in patients who started adjuvant treatment earlier. The overall survival rate was statistically higher in patients receiving a special treatment for tumor recurrence compared to that in patients receiving symptomatic therapy. The evaluation of molecular-genetic prognostic factors showed no statistically significant differences in survival among patients with methylated and nonmethylated MGMT promoter. The presence of IDH1 mutations was identified in only one case. Evaluation of prognostic factors does not allow identification of clinical and molecular biological factors that group patients with hypersensitivity to the proposed treatment regimen. However, high rates of overall and disease-free survival, even in patients with non-methylated MGMT, allow us to recommend this treatment modality for patients with newly diagnosed glioblastoma.

глиобластомафакторы прогнозатермохимиолучевая терапиялокальная гипертермиятранскраниальная гипертермиярадиосенсибилизацияglioblastomaprognostic factorsthermochemoradiotherapylocal hyperthermiatranscranial hyperthermiaradiosensitizationReferencesКобяков Г.Л., Смолин А.В., Бекяшев А.Х., Абсалямова О.В., Кобякова Е.А., Поддубский А.А., Иноземцева М.В. Лечение рецидива глиобластомы: есть ли успехи? Опухоли головы и шеи. 2014; 3: 12–20.Kobyakov G.L., Smolin A.V., Bekyashev A.Kh., Absalyamova O.V., Kobyakova E.A., Poddubsky A.A., Inozemtseva M.V. Treatment for recurrent glioblastoma: are there successes? Head and neck tumors. 2014; 3: 12–20. (in Russian).Stupp R., Taillibert S., Kanner A.A., Kesari S., Steinberg D.M., Toms S.A., Taylor L.P., Lieberman F., Silvani A., Fink K.L., Barnett G.H., Zhu J., Henson J.W., Engelhard H.H., Chen T.C., Tran D.D., Sroubek J., Tran N.D., Hottinger A.F., Landolfi J., Desai R., Caroli M., Kew Y., Honnorat J., Idbaih A., Kirson E.D., Weinberg U., Palti Y., Hegi M.E., Ram Z. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma. A Randomized Clinical Trial. JAMA. 2015; 314 (23): 2535–2543. doi:10.1001/jama.2015.16669.Stupp R., Taillibert S., Kanner A.A., Kesari S., Steinberg D.M., Toms S.A., Taylor L.P., Lieberman F., Silvani A., Fink K.L., Barnett G.H., Zhu J., Henson J.W., Engelhard H.H., Chen T.C., Tran D.D., Sroubek J., Tran N.D., Hottinger A.F., Landolfi J., Desai R., Caroli M., Kew Y., Honnorat J., Idbaih A., Kirson E.D., Weinberg U., Palti Y., Hegi M.E., Ram Z. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma. A Randomized Clinical Trial. JAMA. 2015; 314 (23): 2535–2543. doi:10.1001/jama.2015.16669.Tini P., Miracco C., Toscano M., Palumbo S., Comincini S., Gravina G.L., Pirtoli L. Clinical, Pathological, and Molecular Prognostic Parameters in Glioblastoma Patients Undergoing Chemo-and Radiotherapy. Radiobiology of Glioblastoma. Springer International Publishing. 2016; 101–120. doi:10.1007/978-3-319-28305-0_7.Tini P., Miracco C., Toscano M., Palumbo S., Comincini S., Gravina G.L., Pirtoli L. Clinical, Pathological, and Molecular Prognostic Parameters in Glioblastoma Patients Undergoing Chemo-and Radiotherapy. Radiobiology of Glioblastoma. Springer International Publishing. 2016; 101–120. doi:10.1007/978-3-319-28305-0_7.Tamimi A.F., Juweid M. Epidemiology and Outcome of Glioblastoma. Glioblastoma. Codon Publications, Brisbane, Australia. 2017; 143–153. doi: 10.15586/codon.glioblastoma.2017.ch8.Tamimi A.F., Juweid M. Epidemiology and Outcome of Glioblastoma. Glioblastoma. Codon Publications, Brisbane, Australia. 2017; 143–153. doi: 10.15586/codon.glioblastoma.2017.ch8.Осинов И.К., Мусабаева Л.И., Чойнзонов Е.Л., Нечитайло М.Н., Рябова А.И. Влияние факторов прогноза на результаты химиолучевой терапии больных злокачественными глиомами головного мозга. Медицинская радиология и радиационная безопасность. 2012; 57 (4): 13–20.Osinov I.K., Musabaeva L.I., Choynzonov E.L., Nechitaylo M.N., Ryabova A.I. Impact of Clinical Prognostic Factors on Outcomes of Chemoradiotherapy in Patients with Malignant Gliomas. Мedical Radiology and Radiation Safety. 2012; 57 (4): 13–20. (in Russian).Измайлов Т.Р. Клинико-генетические факторы, влияющие на результаты комплексного лечения пациентов с первичной глиобластомой головного мозга. Трудный пациент. 2016; 14 (1): 29–33.Izmailov T.R. Clinical Genetic Factors Affecting the Results of Complex Treatment of Patients with Primary Brain Glioblastoma. Difficult Patient. 2016; 14 (1): 29–33. (in Russian).Ohgaki H., Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013 Feb 15; 19 (4): 764–72. doi: 10.1158/1078-0432.CCR-12-3002.Ohgaki H., Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013 Feb 15; 19 (4): 764–72. doi: 10.1158/1078-0432.CCR-12-3002.Рыжова М.В., Шишкина Л.В., Желудкова О.Г., Голанов А.В., Горелышев С.К., Пицхелаури Д.И., Бекяшев А.Х., Кобяков Г.Л., Абсалямова О.В., Сычева Р.В., Коршунов А.Г. Cравнительная характеристика генетических аберраций в глиобластомах у детей и взрослых. Вопросы нейрохирургии им. Н.Н. Бурденко. 2014; 78 (2): 3–11.Ryzhova M.V., Shishkina L.V., Zheludkova O.G., Golanov A.V., Gorelyshev S.K., Pitskhelauri D.I., Bekiashev A.Kh., Kobiakov G.L., Absaliamova O.V., Sycheva R.V., Korshunov A.G. Сomparative characteristics of genetic aberrations in glioblastomas in children and adults. Burdenko’s Journal of Neurosurgery. 2014; 78 (2): 3–11. (in Russian).Oei A.L., Vriend L.E.M., Crezee J., Franken N.A.P.., Krawczyk P.M. Effects of hyperthermia on DNA repair pathways: one treatment to inhibit them all. Radiat Oncol. 2015; 10: 165. doi:10.1186/s13014-015-0462-0.Oei A.L., Vriend L.E.M., Crezee J., Franken N.A.P.., Krawczyk P.M. Effects of hyperthermia on DNA repair pathways: one treatment to inhibit them all. Radiat Oncol. 2015; 10: 165. doi:10.1186/s13014-015-0462-0.Behrouzkia Z., Joveini Z., Keshavarzi B., Eyvazzadeh N., Aghdam R.Z. Hyperthermia: How Can It Be Used? Oman Med J. 2016; 31 (2): 89–97. doi: 10.5001/omj.2016.19.Behrouzkia Z., Joveini Z., Keshavarzi B., Eyvazzadeh N., Aghdam R.Z. Hyperthermia: How Can It Be Used? Oman Med J. 2016; 31 (2): 89–97. doi: 10.5001/omj.2016.19.Sneed P.K., Stauffer P.R., McDermott M.W., Diederich C.J., Lamborn K.R., Prados M.D., Chang S., Weaver K.A., Spry L., Malec M.K., Lamb S.A., Brigid V., Davis R.L., Wara W.M., Larson D.A., Phillips T.L., Gutin P.H. Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost ± hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 1998 Jan 15; 40 (2): 287–95. doi: 10.1016/S0360-3016(97)00731-1.Sneed P.K., Stauffer P.R., McDermott M.W., Diederich C.J., Lamborn K.R., Prados M.D., Chang S., Weaver K.A., Spry L., Malec M.K., Lamb S.A., Brigid V., Davis R.L., Wara W.M., Larson D.A., Phillips T.L., Gutin P.H. Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost ± hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 1998 Jan 15; 40 (2): 287–95. doi: 10.1016/S0360-3016(97)00731-1.Maier-Hauff K., Ulrich F., Nestler D., Niehoff H., Wust P., Thiesen B., Orawa H., Budach V., Jordan A. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol. 2011 Jun; 103 (2): 317–24. doi: 10.1007/s11060-010-0389-0.Maier-Hauff K., Ulrich F., Nestler D., Niehoff H., Wust P., Thiesen B., Orawa H., Budach V., Jordan A. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol. 2011 Jun; 103 (2): 317–24. doi: 10.1007/s11060-010-0389-0.Рябова А.И., Новиков В.А., Грибова О.В., Чойнзонов Е.Л., Старцева Ж.А., Боберь Е.Е. Адъювантная химиолучевая терапия на фоне локальной гипертермии в комбинированном лечении первичных глиобластом: предварительные результаты. Сибирский онкологический журнал. 2017; 1 (16): 32–38. doi: 10.21294/1814-4861-2017-161-32-38.Ryabova A.I., Novikov V.A., Gribova O.V., Choinzonov E.L., Startseva Zh.A., Bober E.E. Adjuvant chemoradiotherapy with local hyperthermia in combined treatment of primary glioblastoma: preliminary results. Siberian Journal of Oncology. 2017; 1 (16): 32–38. (in Russain). doi: 10.21294/1814-4861-2017-161-32-38.Абсалямова О.В., Аникеева О.Ю., Голанов А.В., Кобяков Г.Л., Коновалов А.Н., Корниенко В.Н., Кривошапкин А.Л., Лошаков В.А., Олюшин В.Е., Потапов А.А., Рыжова М.В., Таняшин С.В., Трунин Ю.Ю., Улитин А.Ю., Шишкина Л.В. Клинические рекомендации по лечению первичных опухолей центральной нервной системы. 2013 [Internet]. URL: http://www.nsi.ru/scientificactivity/publications/id/10182 (дата обращения 04.03.2018).Absalyamova O.V., Anikeeva O.Yu., Golanov A.V., Kobyakov G.L., Konovalov A.N., Kornienko V.N., Krivoshapkin A.L., Loshakov V.A., Olyushin V.E., Potapov A.A., Ryzhova M.V., Tanyashin S.V., Trunin Yu.Yu., Ulitin A.Yu., Shishkina L.V. Clinical guidelines for the treatment of primary tumors of the central nervous system. 2013 [Internet]. URL: http://www.nsi.ru/scientificactivity/publications/id/10182 (cited 04.03.2018). (in Russian).Louis D.N., Perry A., Reifenberger G., von Deimling A., FigarellaBranger D., Cavenee W.K., Ohgaki H., Wiestler O.D., Kleihues P., Ellison D.W. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016 Jun; 131 (6): 803–20. doi: 10.1007/s00401-016-1545-1.Louis D.N., Perry A., Reifenberger G., von Deimling A., FigarellaBranger D., Cavenee W.K., Ohgaki H., Wiestler O.D., Kleihues P., Ellison D.W. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016 Jun; 131 (6): 803–20. doi: 10.1007/s00401-016-1545-1.Wen P.Y., Macdonald D.R., Reardon D.A., Cloughesy T.F., Sorensen A.G., Galanis E., DeGroot J., Wick W., Gilbert M.R., Lassman A.B., Tsien C., Mikkelsen T., Wong E.T., Chamberlain M.C., Stupp R., Lamborn K.R., Vogelbaum M.A., van den Bent M.J., Chang S.M. Updated response assessment criteria for high-grade gliomas: response assessment in neurooncology working group. J Clin Oncol. 2010 Apr 10; 28 (11): 1963–72. doi: 10.1200/JCO.2009.26.3541.Wen P.Y., Macdonald D.R., Reardon D.A., Cloughesy T.F., Sorensen A.G., Galanis E., DeGroot J., Wick W., Gilbert M.R., Lassman A.B., Tsien C., Mikkelsen T., Wong E.T., Chamberlain M.C., Stupp R., Lamborn K.R., Vogelbaum M.A., van den Bent M.J., Chang S.M. Updated response assessment criteria for high-grade gliomas: response assessment in neurooncology working group. J Clin Oncol. 2010 Apr 10; 28 (11): 1963–72. doi: 10.1200/JCO.2009.26.3541.Nakagawa K., Hills N.K., Kamel H., Morabito D., Patel P.V., Manley G.T., Hemphill J.C. III. The effect of decompressive hemicraniectomy on brain temperature after severe brain injury. Neurocrit Care. 2011 Aug; 15 (1): 101–6. doi: 10.1007/s12028-010-9446-y.Nakagawa K., Hills N.K., Kamel H., Morabito D., Patel P.V., Manley G.T., Hemphill J.C. III. The effect of decompressive hemicraniectomy on brain temperature after severe brain injury. Neurocrit Care. 2011 Aug; 15 (1): 101–6. doi: 10.1007/s12028-010-9446-y.Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., Ludwin S.K., Allgeier A., Fisher B., Belanger K., Hau P., Brandes A.A., Gijtenbeek J., Marosi C., Vecht C.J., Mokhtari K., Wesseling P., Villa S., Eisenhauer E., Gorlia T., Weller M., Lacombe D., Cairncross J.G., Mirimanoff R.O. European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009 May; 10 (5): 459–66. doi: 10.1016/S1470-2045(09)70025-7.Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., Ludwin S.K., Allgeier A., Fisher B., Belanger K., Hau P., Brandes A.A., Gijtenbeek J., Marosi C., Vecht C.J., Mokhtari K., Wesseling P., Villa S., Eisenhauer E., Gorlia T., Weller M., Lacombe D., Cairncross J.G., Mirimanoff R.O. European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009 May; 10 (5): 459–66. doi: 10.1016/S1470-2045(09)70025-7.Осинов И.К., Мусабаева Л.И., Нечитайло М.Н., Чойнзонов Е.Л. Химиолучевое лечение злокачественных глиом головного мозга с применением препарата темодал. Сибирский онкологический журнал. 2009; 6: 5–11.Osinov I.K., Musabaeva L.I., Nechitailo M.N., Choynzonov E.L. Chemoradiotherapy with Temadol for malignant gliomas. Siberian Journal of Oncology. 2009; 6: 5–11. (in Russian).Chinot O.L., Wick W., Mason W., Henriksson R., Saran F., Nishikawa R., Carpentier A.F., Hoang-Xuan K., Kavan P., Cernea D., Brandes A.A., Hilton M., Abrey L., Cloughesy T. Bevacizumab plus radiotherapytemozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014; 370 (8): 709–22. doi: 10.1056/NEJMoa1308345.Chinot O.L., Wick W., Mason W., Henriksson R., Saran F., Nishikawa R., Carpentier A.F., Hoang-Xuan K., Kavan P., Cernea D., Brandes A.A., Hilton M., Abrey L., Cloughesy T. Bevacizumab plus radiotherapytemozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014; 370 (8): 709–22. doi: 10.1056/NEJMoa1308345.Gilbert M.R., Dignam J.J., Armstrong T.S., Wefel J.S., Blumenthal D.T., Vogelbaum M.A., Colman H., Chakravarti A., Pugh S., Won M., Jeraj R., Brown P.D., Jaeckle K.A., Schiff D., Stieber V.W., Brachman D.G., Werner-Wasik M., Tremont-Lukats I.W., Sulman E.P., Aldape K.D., Curran W.J. Jr., Mehta M.P. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20; 370 (8): 699–708. doi: 10.1056/NEJMoa1308573.Gilbert M.R., Dignam J.J., Armstrong T.S., Wefel J.S., Blumenthal D.T., Vogelbaum M.A., Colman H., Chakravarti A., Pugh S., Won M., Jeraj R., Brown P.D., Jaeckle K.A., Schiff D., Stieber V.W., Brachman D.G., Werner-Wasik M., Tremont-Lukats I.W., Sulman E.P., Aldape K.D., Curran W.J. Jr., Mehta M.P. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20; 370 (8): 699–708. doi: 10.1056/NEJMoa1308573.Thumma S.R., Fairbanks R.K., Lamoreaux W.T., Mackay A.R., Demakas J.J., Cooke B.S., Elaimy A.L., Hanson P.W., Lee C.M. Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis. World J Surg Oncol. 2012 May 3; 10 (1): 75. doi:10.1186/14777819-10-75.Thumma S.R., Fairbanks R.K., Lamoreaux W.T., Mackay A.R., Demakas J.J., Cooke B.S., Elaimy A.L., Hanson P.W., Lee C.M. Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis. World J Surg Oncol. 2012 May 3; 10 (1): 75. doi:10.1186/14777819-10-75.Díez Valle R., Tejada Solis S., Idoate Gastearena M.A., García de Eulate R., Domínguez Echávarri P., Aristu Mendiroz J. Surgery guided by 5-aminolevulinic fluorescence in glioblastoma: volumetric analysis of extent of resection in singlecenter experience. J Neurooncol. 2011; 102: 105–113. doi: 10.1007/s11060-010-0296-4.Díez Valle R., Tejada Solis S., Idoate Gastearena M.A., García de Eulate R., Domínguez Echávarri P., Aristu Mendiroz J. Surgery guided by 5-aminolevulinic fluorescence in glioblastoma: volumetric analysis of extent of resection in singlecenter experience. J Neurooncol. 2011; 102: 105–113. doi: 10.1007/s11060-010-0296-4.Delgado-López P.D., Corrales-García E.M. Survival in glioblastoma: a review on the impact of treatment modalities. Clin Transl Oncol. 2016 Nov; 18 (11): 1062–1071.Delgado-López P.D., Corrales-García E.M. Survival in glioblastoma: a review on the impact of treatment modalities. Clin Transl Oncol. 2016 Nov; 18 (11): 1062–1071.Lawrence Y.R., Blumenthal D.T., Matceyevsky D., Kanner A.A., Bokstein F., Corn B.W. Delayed initiation of radiotherapy for glioblastoma: how important is it to push to the front (or the back) of the line? J Neurooncol. 2011 Oct; 105 (1): 1–7. doi: 10.1007/s11060-011-0589-2.Lawrence Y.R., Blumenthal D.T., Matceyevsky D., Kanner A.A., Bokstein F., Corn B.W. Delayed initiation of radiotherapy for glioblastoma: how important is it to push to the front (or the back) of the line? J Neurooncol. 2011 Oct; 105 (1): 1–7. doi: 10.1007/s11060-011-0589-2.Nathan J.K., Brezzell A.L., Kim M.M., Leung D., Wilkinson D.A., Hervey-Jumper S.L. Early initiation of chemoradiation following index craniotomy is associated with decreased survival in high-grade glioma. Journal of neuro-oncology. 2017; 135 (2): 325–333. doi: 10.1007/s11060-017-2577-7.Nathan J.K., Brezzell A.L., Kim M.M., Leung D., Wilkinson D.A., Hervey-Jumper S.L. Early initiation of chemoradiation following index craniotomy is associated with decreased survival in high-grade glioma. Journal of neuro-oncology. 2017; 135 (2): 325–333. doi: 10.1007/s11060-017-2577-7.Vuksanovic V., Sheppard L.W., Stefanovska A. Nonlinear Relationship between Level of Blood Flow and Skin Temperature for Different Dynamics of Temperature Change. Biophys J. 2008; 94 (10): L78–80. doi: 10.1529/biophysj.107.127860.Vuksanovic V., Sheppard L.W., Stefanovska A. Nonlinear Relationship between Level of Blood Flow and Skin Temperature for Different Dynamics of Temperature Change. Biophys J. 2008; 94 (10): L78–80. doi: 10.1529/biophysj.107.127860.Theeler B.J., Yung W.K., Fuller G.N., De Groot J.F. Moving toward molecular classification of diffuse gliomas in adults. Neurology. 2012; 79 (18): 1917–26. doi: 10.1212/WNL.0b013e318271f7cb.Theeler B.J., Yung W.K., Fuller G.N., De Groot J.F. Moving toward molecular classification of diffuse gliomas in adults. Neurology. 2012; 79 (18): 1917–26. doi: 10.1212/WNL.0b013e318271f7cb.Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., Kros J.M., Hainfellner J.A., Mason W., Mariani L., Bromberg J.E.C., Hau P., Mirimanoff R.O., Cairncross J.G., Janzer R.C., Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352: 997–1003. doi: 10.1056/NEJMoa043331.Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., Kros J.M., Hainfellner J.A., Mason W., Mariani L., Bromberg J.E.C., Hau P., Mirimanoff R.O., Cairncross J.G., Janzer R.C., Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352: 997–1003. doi: 10.1056/NEJMoa043331.

The authors declare that there are no conflicts of interest present.